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Abstract We show by site-directed mutagenesis that the
catalytic residues of mammalian legumain, a recently discovered
lysosomal asparaginycysteine endopeptidase, form a catalytic
dyad in the motif His-Gly-spacer-Ala-Cys. We note that the
same motif is present in the caspases, aspartate-specific
endopeptidases central to the process of apoptosis in animal
cells, and also in the families of clostripain and gingipain which
are arginyl/lysyl endopeptidases of pathogenic bacteria. We
propose that the four families have similar protein folds, are
evolutionarily related in clan CD, and have common character-
istics including substrate specificities dominated by the interac-
tions of the S1 subsite.
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Key words: Legumain; Caspase; Clostripain; Gingipain;
Peptidase clan
1. Introduction
Legumain (EC 3.4.22.34) is a cysteine endopeptidase that
was until recently known only from plants [1,2] and Schisto-
soma [3]. In plants there is abundant evidence that legumain
performs a protein-processing function, causing limited pro-
teolysis of precursor proteins and protein splicing [2,4]. Fol-
lowing the discovery of legumain in mammalian cells, and the
cloning and sequencing of legumain from human [5] and
mouse [6], we have shown the enzyme to be predominantly
lysosomal [6], but it has strict speci¢city for the hydrolysis of
bonds on the carboxyl side of asparagine which is very di¡er-
ent from that of any other lysosomal endopeptidase and
adapts it particularly for limited proteolysis. Consistent with
this, there is evidence for a key role of legumain in the proc-
essing of a bacterial antigen for the MHC class II system in
the lysosomal/endosomal system of antigen presenting cells [7]
and it also processes progelatinase A to the active enzyme
(J.-M. Chen and A.J. Barrett, unpublished results).
The amino acid sequence of legumain shows it to belong to
a distinct family of cysteine endopeptidases that has been
termed peptidase family C13. (This and other identi¢ers for
peptidase families and clans are as de¢ned in the MEROPS
database [8,9].) We here describe the identi¢cation of the cat-
alytic residues of legumain, and show how they reveal rela-
tionships between family C13 and several other families of
cysteine endopeptidases.
2. Materials and methods
2.1. Mutagenesis and plasmid construction of legumain mutants
Mouse legumain cDNA was removed from the plasmid construct
pCMVmusleg [6] with EcoRI and XhoI and subcloned into the pCR-
Script Ampr SK(+) vector (Stratagene) at the same sites to produce a
pCRmusleg construct. Mutagenesis was performed by PCR site-di-
rected mutagenesis as described by Picard et al. [10] with modi¢ca-
tions. Six mutagenic primers based on the nucleotide sequence of
human legumain were designed to generate mutants H47A, C52S,
H150A, H164A, C191S, and S195A. These primers with underlined
nucleotides encoding the mutated residues were: 5P-GGTATAATTA-
TAGGGCACAGGCAGACGC-3P for H47A, 5P-AGGCAGACGC-
GTCCCATGCCTAC-3P for C52S, 5P-CATTTACTTCACTGAC-
GCTGGATCTACTGG-3P for H150A, 5P-CTAATGATGATCTT-
GCTGTCAAGGACCTGA-3P for H164A, 5P-CTACATTGAAG-
CCTCTGAGTCTGGGTCC-3P for C191S, and 5P-GTGAGTC-
TGGGGCTATGATGAACC-3P for S195A. Since the mutagenic
primers were based on the human legumain sequence, some silent
mutations were introduced into the mouse legumain constructs, and
in mutant H150A the residue Ala-152 of mouse legumain was re-
placed by the Ser corresponding in the human sequence. Polymerase
Pfu was used for all PCR reactions with a typical run of 95‡CU1 min,
48‡CU1 min, 72‡CU2 min for 30 cycles. Introduction of the mutated
codon was performed by PCR using a mutagenic primer, the down-
stream primer of mouse legumain (5P-CTGGTGTTGGTGTGGG-
ACTTGACC-3P), and pCMVmusleg as the template to generate a
megaprimer. The megaprimer and the legumain-speci¢c upstream
primer (5P-GACGCCCGGAATTCCCACGGTT-3P) were used for
the second run of PCR with the same template to generate an
880-bp product containing the mutated nucleotide(s). This product
was puri¢ed from the agarose gel by use of the Gene Clean Kit
(BIO 101) and double digested with EcoRI and HincII. Wild-type
pCRmusleg was similarly digested with EcoRI and HincII to remove
the 880-bp wild type sequence, and the mutated PCR product was
ligated into this vector to generate the mutated forms of pCRmusleg.
Plasmid DNA of wild-type and mutant pCRmusleg was propagated
in E. coli DH10B (Life Technologies) or XL10-gold (Stratagene) and
puri¢ed by standard procedures [11]. The sequences of all mutated
constructs were con¢rmed by sequencing. The full length cDNA of
mutant legumain was then excised from the cloning vector pCR-
musleg with EcoRI and XhoI and cloned into the mammalian expres-
sion vector pCMV-SPORT2 for transient expression.
2.2. Cell culture and transfection
Human embryonic kidney (HEK) 293 cells (ATCC no. CRL 1573)
were maintained in minimal Eagle’s medium supplemented with 10%
fetal bovine serum and antibiotics. The calcium phosphate precipita-
tion method was used to transfect HEK 293 cells with the wild-type
and mutant legumain constructs as described [6].
2.3. Detection of recombinant legumain and enzymatic assays
HEK 293 cells transfected with legumain constructs and mock-
transfected cells were harvested three days after transfection. Cells
were disrupted by three cycles of freeze and thaw in the lysis bu¡er
(0.1 M sodium citrate, pH 5.8, containing 1 mM EDTA and 1% n-
octyl L-D-glucopyranoside). Cell lysates were collected after centrifu-
gation at 18 000Ug for 10 min. The recombinant protein of wild-type
and mutant legumain expressed in the cell lysate were detected by
SDS-PAGE immunoblot developed with a polyclonal antibody spe-
ci¢c to pig legumain [6]. To measure the enzymatic activity of re-
combinant legumain, lysate (5 Wl) was placed in the well of a 96-
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well microtiter plate and the reaction was started by addition of 120 Wl
of benzyloxycarbonyl-Ala-Ala-Asn-7-(4-methyl)coumarylamide (Z-
Ala-Ala-Asn-NHMec) solution in assay bu¡er (39.5 mM citric acid,
121 mM Na2HPO4, pH 5.8, containing 1 mM DTT, 1 mM EDTA
and 0.1% CHAPS) to give 10 WM ¢nal concentration of the substrate.
The plates were incubated at 25‡C and readings of £uorescence (ex-
citation 360 nm, emission 460 nm) were taken at 10 and 130 min in a
PerSeptive Biosystems CytoFluor II £uorescence plate reader. The
change between the two readings was the measure of activity. Speci¢c
legumain activity was obtained by subtracting the control value of
mock-transfected cells.
3. Results and discussion
3.1. Catalytic dyad of legumain
The catalytic residues in all known cysteine endopeptidases
are a dyad of cysteine and histidine, which may occur in either
order, cysteine^histidine or histidine^cysteine, in the amino
acid sequence. Accordingly, the residues His-47, Cys-52,
His-150 and Cys-191 were selected as targets for mutagenesis
by inspection of an alignment of the sequences for family C13,
part of which is shown in Fig. 1. Site directed mutagenesis was
done as described in Section 2 to generate mutant constructs
H47A, C52S, H150A and C191S. Two additional constructs,
H164A and S195A, were made as controls. Wild-type and
mutant proteins were transiently expressed in HEK 293 cells
under the control of the CMV promoter. Immunoblotting
analysis showed that recombinant proteins from all constructs
were expressed and processed to mature forms similar in mo-
lecular size (35 kDa) to the wild-type protein (Fig. 2a). The
H150A mutant was expressed about four-fold less e⁄ciently
than the other forms as judged by inspection of the immuno-
blots.
Assays of legumain activity in extracts of cells expressing
the mutated forms of the enzyme revealed that mutants
H150A and C191S were completely inactive, whereas H47A
and C52S were 54% and 101%, respectively, as active as the
wild type. The two control mutants, H164A and S195A, were
also as active as the wild type (Fig. 2b). In separate experi-
ments (not shown) the C191S mutant of human legumain was
made and again was found to be expressed normally but to be
inactive. We conclude that His-150 and Cys-191 are essential
for the catalytic activity of legumain and can be assumed to
represent the catalytic dyad of the enzyme. The legumain of
Schistosoma mansoni apparently lacks Cys-191 (Fig. 1), and
we assume that the published sequence is that of an inactive
variant of the enzyme. This would be consistent with the fail-
ure of Goºtz and Klinkert [12] to detect activity of the Schis-
tosoma mansoni enzyme expressed in insect cells, but Cys-191
is present in the S. japonicum sequence. The other generally
conserved cysteine residue, Cys-52, is absent from the human
GPI8 protein that catalyses the attachment of glycosylphos-
phatidylinositol anchors to proteins [13,14].
3.2. An active site motif recognised in legumain is present in
other families
The amino acid sequence of the segment of the polypeptide
chain containing the catalytic residues identi¢ed in legumain
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Fig. 1. Selection of candidate catalytic residues for mutagenesis. Only the parts of the sequences containing well-conserved residues of cysteine
or histidine are shown. The sequences (numbered according to mouse preprolegumain [6]) are: AJ000990, mouse legumain; Q99538, human le-
gumain; Q92643, human GPI8 protein; P49046, jack bean (Canavalia ensiformis) asparaginyl endopeptidase; P49042, castor bean (Canavalia en-
siformis) vacuolar processing enzyme; P09841, Schistosoma mansoni haemoglobinase; and P42665, Schistosoma japonicum haemoglobinase.
Fig. 2. Expression and activity of wild-type and mutant forms of le-
gumain. a: Lysates (5 Wl except H150A 20 Wl) of HEK 293 cells
transfected with legumain constructs in the pCMV-SPORT2 vector,
or mock-transfected cells, were run in SDS-PAGE, and transblotted
for the detection of legumain as described in Section 2. b: Legu-
main activity of cell lysates as in a, assayed with Z-Ala-Ala-Asn-
NHMec as described in Section 2. The blank value of activity in
the mock-transfected cells that has been subtracted is 622 £uores-
cence units. Bars show S.D. (n = 3).
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was compared with sequences of cysteine peptidases in other
families. As shown in Fig. 3, it was found that a motif His-
Gly-spacer-Ala-Cys could be recognised not only in the legu-
main family but also in the families of caspase-1 (C14), clos-
tripain (C11) and gingipain R (C25). The caspases are mam-
malian cytosolic endopeptidases that play key roles in
apoptosis, whereas clostripain and gingipain are cysteine en-
dopeptidases from the pathogenic bacteria Clostridium histo-
lyticum and Porphyromonas gingivalis, respectively [15,16].
The cysteine residues in this motif have already been identi¢ed
as the catalytic cysteines of all three of these other families
[17^19] and the histidine has been identi¢ed as catalytic in
C14 [18] and suggested tentatively for C25 [19]. Closely pre-
ceding each of the catalytic residues in all four families is a
block of four hydrophobic amino acids (marked in blue in
Fig. 3a). The corresponding parts of the secondary structures
predicted for mouse legumain, clostripain, and gingipain R by
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Fig. 3. Alignment of the catalytic sites of cysteine endopeptidases of families of legumain (C13), caspase-1 (C14), clostripain (C11) and gingi-
pain R (C25). a: The sequence segments containing the known or putative catalytic residues (magenta and yellow) in each of the four families
were aligned manually by the introduction of gap residues ‘.’. It can be seen that two or three residues N-terminal to each of the catalytic resi-
dues there is a block of four predominantly hydrophobic residues (green). Other residues that tend to be conserved between the families are
printed in white on black. Asterisks are placed over the His and Cys residues in each family for which they have been identi¢ed experimentally
as catalytic, and in addition the His residue in family C25 was proposed to be catalytic by Pavlo¡ et al. [19] on the basis of its conservation in
the family. Key to sequences: AL000990, mouse legumain; Q99538, human legumain; P49046, jack bean (Canavalia ensiformis) asparaginyl en-
dopeptidase; P42665, Schistosoma japonicum haemoglobinase; P49048, Caenorhabditis elegans hypothetical protein T05E11.6; Q92643, human
GPI8 protein; P42574, human caspase 3; P55210, human caspase 7; P55212, human caspase 6; O01382, Drosophila melanogaster caspase;
P29466, human caspase 1; P42573, Caenorhabditis elegans CED3 protein; P09870, Clostridium histolyticum K-clostripain; Q51816, Porphyromo-
nas gingivalis gingipain R. b: The corresponding secondary structures are those determined crystallographically for human caspase-1 (family
C14; PDB 1IBC) or predicted for the C13, C11 and C25 families by the PHD program [20]. The L-strand residues are marked ‘b’, the K-helix
residues ‘a’ and the turn residues ‘t’. Both catalytic residues in family C14 are preceded by L-strands (strands S3 and S4, respectively) and with
one exception these strands (containing the blocks of hydrophobic residues noted in a above) are predicted for the other families. The second-
ary structure elements shown here for the caspase family can be seen in the three-dimensional representation of Fig. 4.
C
Fig. 4. Tertiary structure of part of the caspase-1 molecule (pepti-
dase family C14) drawn from PDB record 1IBC by use of the
MOLSCRIPT program [26]. Shown in green are the two L-strands
that support the catalytic residues, histidine (pink) and cysteine (yel-
low), and the remainder of the segment included in the alignment of
Fig. 3 is coloured in cyan.
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the PHD program [20] are shown in Fig. 3b, and are generally
in good agreement with the structure known for caspase-1
[18]. The longest spacer sequence exists in clostripain, but it
is notable that the maturation of clostripain normally involves
the autolytic excision of the nonapeptide 156-159E, although
this is not required for activity [21]. As shown in Fig. 4, the
catalytic residues of caspase-1 occur at the ends of two paral-
lel L-strands. These are two central strands in a set of six that
form a L-sheet at the core of the molecule, and the blocks of
hydrophobic residues seen in the alignment are contained in
the strands. This arrangement is expected to be mirrored in
the other families.
3.3. The active site motif is unique
We next asked whether the sequence motif that contains the
catalytic dyad in each of these four families of cysteine endo-
peptidases occurs in other proteins too. First, Motif 1 (Table
1) was formulated to include the blocks of hydrophobic res-
idues preceding each of the catalytic residues as highlighted in
Fig. 3, and the two non-hydrophobic residues immediately
preceding the catalytic cysteine, and this was used to search
the protein sequence databases. All 37 sequences retrieved
proved to be known members of peptidase families C11,
C13, C14 or C25, but many peptidases of these families
were not recognised by Motif 1, so the more relaxed Motif
2 was constructed. This allowed a greater or lesser number of
residues spacing the catalytic His and Cys, any hydrophobic
residue at any position in the blocks preceding each member
of the catalytic dyad, and restrictions on residue 189. With
Motif 2, 66 hits were retrieved, and these included all but
seven of the known members of the four families together
with just three apparently unrelated false positive sequences
all for hypothetical proteins (Table 1).
It is evident from these results that Motif 2 is very e¡ective
in screening protein sequences for the peptidases of just four
families. Sequences belonging to all other known families of
cysteine peptidases were quite unrecognised, notably including
those from the papain (C1) and the calpain (C2) families, and
those of many viruses.
3.4. Four families in clan CD
We believe that these ¢ndings represent strong evidence that
the four families of cysteine peptidases C11, C13, C14 and
C25 are evolutionarily related, albeit very distantly, and that
they retain topological similarities in the catalytic sites. Test-
able predictions from this proposal are that the same histidine
residue (His-150 in Fig. 3) will be found experimentally to be
essential for catalysis in clostripain and gingipain R, and that
when three-dimensional structures are determined for repre-
sentatives of families C11, C13 and C25 they will show sim-
ilarities to those of the caspases.
Family C14 has already been assigned to clan CD in the
classi¢cation of the MEROPS database [9] on the grounds of
its distinctive protein fold, and has been the only family in this
clan, but we now propose that families C11, C13 and C25
should be added to clan CD. One of the purposes of assem-
bling clans of peptidases is the expectation that the evolution-
ary and structural similarities between the peptidases in re-
lated families will tend to be re£ected in similar
enzymological properties and sometimes even functions. The
enzymes of clan CD do indeed have striking similarities in
catalytic activity. All are very speci¢c endopeptidases, with a
strict requirement for the side chain of the P1 amino acid
residue that provides the carbonyl group in the scissile peptide
bond: arginine for clostripain (family C11), asparagine for
legumain (C13), aspartate for the caspases (C14) and arginine
or lysine for gingipain R or gingipain K, respectively, in fam-
ily C25. This type of speci¢city is not characteristic of the
more familiar but quite unrelated cysteine peptidases that
are homologues of papain in clan CA, which generally show
broad speci¢city with greatest selectivity in subsite S2 [22,23].
There are also similarities in inhibition characteristics. All of
the peptidases in the families now assigned to clan CD are
resistant to irreversible inhibition by compound E-64 [L-3-car-
boxy-2,3-trans-epoxypropionyl-leucylamido-(4-guanidino)bu-
tane], which has often been thought of as a general reagent for
cysteine endopeptidases. (Reversible inhibition of gingipain R
and clostripain is attributable to the fact that E-64 is an argi-
nine analogue [24,25].) However, the cysteine endopeptidases
of clan CD are susceptible to peptide aldehyde and peptidyl-
chloromethane inhibitors, and it now appears that it may be
possible to take advantage of successes in the structure-based
design of inhibitors for the caspases to design inhibitors for
enzymes in the other families, modifying speci¢city simply by
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Table 1
Database searches for proteins containing sequence motifs based on












C13 O24325, O24326, O46047, P42665, P49018, P49042, P49043,
P49044, P49045, P49046, P49047, P49048, Q39044, Q39119,
Q92643, Q99538
C14 O01382, O02002, O02229, O02433, O08736, O08738,
O14676, O14822, O35397, O35669, O42284, O55194,
P29452, P29466, P29594, P42573, P42574, P42575, P43527,
P45436, P49662, P51878, P55210, P55211, P55212, P55213,
P55214, P55215, P55865, P55866, P55867, P70343, P70677,
P89116, P97864, Q14790, Q60431, Q92851, Q98943
C25 O33441, P28784, P95493, Q51816, Q51838, Q51839, Q51844
Sequences not in families C11, C13, C14 or C25
O22161, O28117, Q53839
Sequences not retrieved although recognised members of families C11,




C25 O07442, P72194, Q51817, Q51818
The two motifs were formulated according to the conventions of
PROSITE [27] and used to search the SWISSPROT and TREMBL
databases (10 August 1998; 223 599 sequences) by use of the SCAN-
PROSITE program at the ExPASy server [27]. Motif 1 retrieved the
37 sequences underlined, all of which are recognised members of fam-
ilies C11, C13, C14 or C25. Motif 2 retrieved 66 sequences of which
63 are recognised members of these families, but three are not. Seven
sequences of known members of families C11, C13, C14 or C25 were
not retrieved by either motif. These were O24539, Vicia narbonensis
legumain (with Cys-147); P09841, Schistosoma mansoni haemoglobi-
nase (with Cys191Asn replacement); P42576, isoform of the positive
P42575; O07442, P72194 and Q51817, Q51818, aberrant forms of
gingipain. Five sequence fragments that did not overlap the consensus
sequence were ignored.
J.-M. Chen et al./FEBS Letters 441 (1998) 361^365364
matching the di¡erent P1 requirements in a similar active site
geometry.
3.5. Evolution of clan CD
The families of clan CD are widely distributed. Clostripain,
the only known member of family C11, occurs in Gram-pos-
itive bacteria, and the gingipains of family C25 in Gram-neg-
ative bacteria. In contrast, members of family C13 are known
from plants, fungi and animals, and the caspases of family
C14 are known only from animals. The idea that these four
families are derived from a common ancestor raises the ques-
tion of the route by which the caspases and the legumains
reached mammals following the origin of the clan presumably
in the prebiotic genote. The eukaryote sequences are very
di¡erent from those in bacteria, and thus give no indication
of horizontal transfer from bacteria to eukaryotes. None of
the four families is yet reported to be represented in archaea
or protista, but it seems that representatives of the clan must
have existed there at some time, and we suggest they may yet
be found in the modern members of these groups.
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